63M-2.054 Methicillin Resistant Staphylococcus Aureus (MRSA).
- (1) Each facility’s DHA or designee shall be responsible for infection control requirements in accordance with the CDC for the identification, evaluation, treatment and containment of Methicillin-Resistant Staphylococcus Aureus (MRSA).
- (2) Youth with open skin infections shall be referred to the DHA, or designee, PA or APRN for a medical evaluation.
- (3) A MRSA infection shall be considered in the differential diagnosis of all youth presenting with skin and soft tissue infections consistent with a staphylococcal infection.
- (4) The DHA or designee or PA or APRN shall determine the necessity for wound incision and drainage, use of warm compresses, and the need for antibiotic therapy.
- (5) The DHA shall re-evaluate a youth at least one week after completion of antibiotic therapy for recurrent skin lesions and/or wound assessment to determine the need for further re-culture and treatment.
- (6) Standard Precautions and/or Contact Precautions shall be used for all care for the prevention of cross-contamination of infection.
- (7) Each facility shall implement environmental sanitation for maintaining infection control and preventing the spread of MRSA infection to others.
- (8) Any youth with a skin infection shall receive infection control education that includes prevention and cross-contamination of infection.
Rulemaking Authority 985.64(2) FS. Law Implemented 985.64(2), 985.145, 985.18 FS. History–New 3-16-14.